Wu HH, Fang SY, Chen YX, Feng LF. Treatment of Pneumocystis jirovecii pneumonia in non-human immunodeficiency virus-infected patients using a combination of trimethoprim-sulfamethoxazole and caspofungin. World J Clin Cases 2022; 10(9): 2743-2750 [PMID: 35434110 DOI: 10.12998/wjcc.v10.i9.2743]
Corresponding Author of This Article
Huan-Huan Wu, MD, Doctor, Department of Respiratory Medicine, Dongyang Hospital Affiliated to Wenzhou Medical University, No. 60 Wuning West Road, Dongyang 322100, Zhejiang Province, China. huanhuan871002@163.com
Research Domain of This Article
Infectious Diseases
Article-Type of This Article
Retrospective Study
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Clin Cases. Mar 26, 2022; 10(9): 2743-2750 Published online Mar 26, 2022. doi: 10.12998/wjcc.v10.i9.2743
Treatment of Pneumocystis jirovecii pneumonia in non-human immunodeficiency virus-infected patients using a combination of trimethoprim-sulfamethoxazole and caspofungin
Huan-Huan Wu, Shuang-Yan Fang, Yan-Xiao Chen, Lan-Fang Feng, Department of Respiratory Medicine, Dongyang Hospital Affiliated to Wenzhou Medical University, Dongyang 322100, Zhejiang Province, China
Author contributions: All authors contributed to the study conception and design; Material preparation and data analysis were performed by Feng LF and Chen YX; The first draft of the manuscript was written by Wu HH; Fang SY re-evaluated and added content on the computed tomography imaging outcomes; All authors were involved in the review of various previous versions of the manuscript; All authors have read and approved the final manuscript.
Institutional review board statement: The study protocol was approved by the Ethics Committee of the Dongyang Hospital Affiliated to Wenzhou Medical University (No. 2021-YX-127).
Conflict-of-interest statement: The authors declare that they have no competing interests.
Data sharing statement: All data generated or analyzed during this study are included in this published article.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Huan-Huan Wu, MD, Doctor, Department of Respiratory Medicine, Dongyang Hospital Affiliated to Wenzhou Medical University, No. 60 Wuning West Road, Dongyang 322100, Zhejiang Province, China. huanhuan871002@163.com
Received: August 24, 2021 Peer-review started: August 24, 2021 First decision: November 17, 2021 Revised: November 19, 2021 Accepted: February 15, 2022 Article in press: February 15, 2022 Published online: March 26, 2022 Processing time: 210 Days and 1.9 Hours
Core Tip
Core tip: Pneumocystis jirovecii pneumonia (PJP) is common in immunocompromised hosts. However, the clinical characteristics of non-human immunodeficiency virus (HIV) infected PJP patients have not been fully elucidated. This was a retrospective study of non-HIV-infected PJP treated with trimethoprim– sulfamethoxazole (TMP-SMX) and caspofungin. Clinical manifestations, treatment and prognosis of the patients were evaluated. Non-HIV-infected PJP patients are characterized by rapid disease progression, high risk of respiratory failure, and high mortality. Early diagnosis and treatment can improve survival in non-HIV-infected PJP patients. The findings of the current study showed that combination of TMP-SMX and caspofungin is effective for non-HIV-infected PJP patients with respiratory failure.
